Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Population

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2025 Feb 21

PMID 39980984

Authors

Rong-Hua Wang

Yin Chen

Ya-Ling Lou

Yu-Liang Lu

Hui-Min Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to elaborate on the incidence, clinical features, and management of immune checkpoint inhibitors (ICIs) related cardiovascular adverse events (CVAEs) in real-world practice.

Patients And Methods: We performed a retrospective chart review study on patients receiving at least one dose of ICI therapy at a Chinese tertiary hospital from March 2020 to March 2021. CVAEs were identified through clinical assessment and the Naranjo algorithm. The management and outcomes of CVAEs were monitored over a median follow-up duration of 8 months.

Results: Among the included 203 patients, 4.4% (9/203) developed CVAEs, including heart failure (n = 3), arrhythmia (n = 2), myocarditis (n = 2), and pericardial disease (n = 2), with a proportion (6/9) tending to be severe (grade 3 or grade 4). CVAEs were more common in older patients (mean age: 73.6 ± 9.2 years) and those with hypertension (p = 0.02) or heart failure (p = 0.01). Adherence to the American Society of Clinical Oncology (ASCO) guidelines for managing CVAEs was low (44%), with most cases showing partial resolution by the last follow-up.

Conclusion: We reported that the incidence of ICI-related CVAEs in the Chinese institution was higher than that in some prior studies. Adherence to guidelines for managing ICI-related CVAEs is found to be suboptimal in real-world practice and highlighted as a needed improvement.

References

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

Nashed A, Zhang S, Chiang C, Zitu M, Otterson G, Presley C . Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunol Immunother. 2021; 70(10):2761-2769. PMC: 10992210. DOI: 10.1007/s00262-021-02880-0. View

Wu N, Feng Y, Kuo Y, Chen W, Wu H, Huang C . Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities. Acta Cardiol Sin. 2022; 38(1):39-46. PMC: 8743480. DOI: 10.6515/ACS.202201_38(1).20210830B. View

Icht O, Darzi N, Shimony S, Jacobi O, Reinhorn D, Landman Y . Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Haemost. 2021; 19(5):1250-1258. DOI: 10.1111/jth.15272. View

Johnson D, Balko J, Compton M, Chalkias S, Gorham J, Xu Y . Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016; 375(18):1749-1755. PMC: 5247797. DOI: 10.1056/NEJMoa1609214. View

Fernandez D, Rahman A, Fernandez N, Chudnovskiy A, Amir E, Amadori L . Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019; 25(10):1576-1588. PMC: 7318784. DOI: 10.1038/s41591-019-0590-4. View

Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D . Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2021; 43(4):280-299. PMC: 8803367. DOI: 10.1093/eurheartj/ehab674. View

Tajiri K, Ieda M . Cardiac Complications in Immune Checkpoint Inhibition Therapy. Front Cardiovasc Med. 2019; 6:3. PMC: 6351438. DOI: 10.3389/fcvm.2019.00003. View

Sun J, Qu Q, Lou Y, Hua Y, Sun G, Sun W . Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. Int J Cardiol. 2021; 344:170-178. DOI: 10.1016/j.ijcard.2021.09.041. View

10.

Ribas A, Wolchok J . Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. PMC: 7391259. DOI: 10.1126/science.aar4060. View

11.

Sharma K, Wang S, Liu Y, Zhang Y, Liu T, Zhang Q . Cardio-oncology in China. Curr Treat Options Oncol. 2023; 24(10):1472-1488. DOI: 10.1007/s11864-023-01123-x. View

12.

Mahmood S, Fradley M, Cohen J, Nohria A, Reynolds K, Heinzerling L . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16):1755-1764. PMC: 6196725. DOI: 10.1016/j.jacc.2018.02.037. View

13.

Waheed N, Fradley M, DeRemer D, Mahmoud A, Shah C, Langaee T . Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology. 2021; 7(1):10. PMC: 7977591. DOI: 10.1186/s40959-021-00097-9. View

14.

Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017; 357:j1415. PMC: 6284230. DOI: 10.1136/bmj.j1415. View

15.

Herrmann J . Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020; 17(8):474-502. PMC: 8782611. DOI: 10.1038/s41569-020-0348-1. View

16.

Dsouza M, Nielsen D, Marie Svane I, Iversen K, Rasmussen P, Madelaire C . The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2020; 42(16):1621-1631. DOI: 10.1093/eurheartj/ehaa884. View

17.

Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

18.

Lyon A, Yousaf N, Battisti N, Moslehi J, Larkin J . Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018; 19(9):e447-e458. DOI: 10.1016/S1470-2045(18)30457-1. View

19.

Teimouri A, Minard L, Scott S, Daniels A, Snow S . Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. Curr Oncol. 2022; 29(5):3104-3117. PMC: 9139722. DOI: 10.3390/curroncol29050252. View

20.

Xu J, Ren J, Mugelli A, Belardinelli L, Keith Jr Jr J, Pelleg A . Age-dependent atrial remodeling induced by recombinant human interleukin-11: implications for atrial flutter/fibrillation. J Cardiovasc Pharmacol. 2002; 39(3):435-40. DOI: 10.1097/00005344-200203000-00015. View